A171901 NSCLC >/=70 YOA - Clinical Trial

What is the Purpose of this Study?

We are doing this study to see how an experimental drug called pembrolizumab (MK-3475) works in your body and against your cancer. We want to find out if the study drug works differently in older adults.

What is the Condition Being Studied?

Advanced non-small cell lung cancer that has spread

Who Can Participate in the Study?

Adults 70 years of age and older who:
- Are diagnosed with non-small cell lung cancer that is stage 4 or has come back
- Have not received an organ transplant
- Have not had chemotherapy for 6 months before joining the study
- Have no cancer treatments planned for 3 months after joining this study

Age Group
Adults

What is Involved?

If you join this study, you will:
- Get the study drug through a vein in your arm (IV) every 21 days or every 42 days
- Choose whether or not you also want to receive standard chemotherapy while you get the study drug
- Fill out surveys about your symptoms and health

Study Details

Full Title
ALLIANCE A171901: OLDER NON-SMALL CELL LUNG CANCER PATIENTS (>/= 70 YEARS OF AGE) TREATED WITH FIRST­LINE MK-3475 (PEMBROLIZUMAB) +/- CHEMOTHERAPY (ONCOLOGIST'S/P ATIENT'S CHOICE)
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00107905
NCT: NCT04533451
Phase
Phase II
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698